Brought to you by 
Genzyme gets rights to Ceregene's Parkinson's drug
Jul 2007
Executive Summary
Ceregene (therapeutics for neurodegenerative disorders) licensed Genzyme exclusive worldwide marketing rights (excluding the US and Canada where Ceregene keeps rights) to its lead compound CERE120 for Parkinson's disease.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme gets rights to Ceregene's Parkinson's drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice